SOURCE: Fresh Start Private Management Inc.

Fresh Start Private Management Inc.

April 26, 2011 06:30 ET

Fresh Start Private Given Speculative Buy Rating and FY12 $0.59 per Share Price Target by Prime Equity Research

Alcohol Treatment Leader Builds Positive Momentum Processing Close to $4 Million for the First Quarter

LOS ANGELES, CA--(Marketwire - Apr 26, 2011) - Fresh Start Private (OTCBB: CEYY), a leader in the alcohol treatment and rehabilitation industry, has been given a Speculative Buy rating and FY12 $0.59 per share price target by Prime Equity Research.

Prime Equity Research noted the following:

"The Company is processing over $3.8 Million dollars in insurance claims at its Orange Country clinic from January 1 to March 30, 2011 and has provided guidance that Company's positive revenue momentum continues as its moves into the second quarter of 2011.

One of the initial primary concerns have partly been allayed with Fresh Start, that being insurance companies are moving to approve and authorize reimbursements for Fresh Start alcohol treatment. Inasmuch as it is an extraordinary accomplishment to have $3.8 million in insurance claims in the first full quarter of operation, it is always questionable if the insurance companies would pay in part, or the entirety, of the bills submitted.

Indeed, with the new signed contract with Aetna Health Management Individual and Family Plan Underwriting Department for the approval of its alcohol treatment program, along with prompt payment terms, a cloud has been lifted over the Fresh Start story. Fresh Start also continues to work with Healthnet, Blue Cross, Kaiser, CIGNA, United Healthcare, Anthem, SSI, Blue Cross, Tri-West, MSI and Presbyterian to get more patients approved for treatment for its revolutionary Naltrexone implant.

Fresh Start has opened one corporate-owned clinic and that this first facility is operational and able to treat up to 15 patients a day with potential revenue of $120 Million per year per clinic. The intent is for FSP to open more clinics in areas that show demand and excellent ROI.

On another note, the recently filed fiscal year-end results for 2010 ending in December 31, relate to prior and distinctly different business operations and do not reflect operations of Fresh Start's alcohol treatment services."

For access to the report and information on Prime Equity Research, LLC please visit the company's website. Interested parties may obtain the report at

About Prime Equity Research

Prime Equity Research was founded and is managed by a team that has been actively involved in the research and finance industry for over 15 years -- dating back to the origins of corporate-sponsored research. Our business is rooted in principles of integrity and fundamentals-driven markets. Our seasoned pool of equity securities analysts have extensive securities market research experience, and are highly qualified and credentialed CFA (Chartered Financial Analyst) charterholders or MBAs. The research we provide is as comprehensive, and unbiased as any on the market. Furthermore, we create strategic partnerships with companies and firms around the world to gain unprecedented domestic and international following of our coverages. Our reports and ratings are used by both institutional and individual investors to obtain accurate, independently-compiled securities data.

About Fresh Start Private

Fresh Start Private is an alcohol addiction, alcohol withdrawal, alcohol abuse treatment and alcohol detox rehabilitation company on the leading edge of the alcohol addiction treatment. The Company has licensed a highly effective treatment that delivers target therapeutic levels of Naltrexone that significantly reduce patients' cravings for alcohol. Please visit

Statements in this press release may be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "optimizing," "potential," "anticipate," "goal," "intend" and similar expressions, as they relate to the company or its management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above and those risks discussed from time to time in Fresh Start filings with the Securities and Exchange Commission. The company notes that the numbers contained in this release are unaudited, and are made in good faith and based on all the financial information available to the company today. Further, past financial business, operations and stock performance are not necessarily indicative of the company's future performance. The opinions expressed in the research report are the analyst's personal views about the company. Definitions of ratings are available to the public and to the analysts. No rating is to be issued that is labeled a recommendation. No analyst may recommend the purchase or the sale of any equity.. The analyst is responsible only to the public and this report is not a service to the company. The report is for information purposes and is not intended as an offering or a solicitation to buy or sell the securities mentioned above. Neither the analyst nor Prime Equity Research owns any equity or debt securities in the analyzed company. Analysts are independent contractors and not employed by Prime Equity Research. The analyst is paid in advance to ensure independent and objective opinions are rendered without conflict. A third-party paid Prime Equity Research $16,000 for independent equity coverage. The following is from the Final Report of the SEC Advisory Committee on Smaller Public Companies, adopted February 21, 2006: "In order to address the need for more independent research for smaller public companies, [the U.S. Securities and Exchange Advisory Committee on Smaller Public Companies recommends] that the Commission: "Maintain policies that allow company-sponsored research to occur with full disclosure by the research provider as to the nature of the relationship with the company being covered. "Entities providing such research should disclose and adhere to a set of ethical standards* that ensure quality and transparency and minimize conflicts of interest."

Contact Information

  • Investor Relations
    Bill Clayton
    Toll Free (877) 521-CEYY (2399)
    Email Contact